Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 2:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Posterior Fossa Tumors Clear all
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Posterior Fossa Ependymal Tumor
Interventions
Metformin, Planned Surgical Resection, Magnetic Resonance Imaging (MRI), Specimen Collection, MR spectroscopy (MRS)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 22, 2026, 2:44 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Gliosarcoma
Interventions
Adavosertib, Laboratory Biomarker Analysis, Pharmacological Study, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
37 Months to 21 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced May 22, 2026, 2:44 AM EDT
Suspended Phase 2 Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
Interventions
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Combination Product
Lead sponsor
SonALAsense, Inc.
Industry
Eligibility
5 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
Interventions
Fimepinostat, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
3 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced May 22, 2026, 2:44 AM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
4 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced May 22, 2026, 2:44 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma, Diffuse Intrinsic Brainstem Glioma, Diffuse Intrinsic Pontine Glioma, DIPG Brain Tumor, H3 K27M
Interventions
SIACI of cetuximab and bevacizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
1 Year to 21 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced May 22, 2026, 2:44 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Posterior Fossa Hemorrhage, Lung Cancer, Flank Pain, Urolithiasis, Focal Hepatic Necrosis
Interventions
Not listed
Lead sponsor
GE Healthcare
Industry
Eligibility
30 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Miwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced May 22, 2026, 2:44 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma (DIPG)
Interventions
Specialized tumor board recommendation, Standard radiation therapy
Other · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 25 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced May 22, 2026, 2:44 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27-Altered, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Echocardiography Test, FACT Complex-targeting Curaxin CBL0137
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 2:44 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma, Ependymoma
Interventions
PEP-CMV vaccine, Tetanus booster, Nivolumab, Temozolomide
Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
4 Years to 25 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2043
U.S. locations
3
States / cities
St Louis, Missouri • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced May 22, 2026, 2:44 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Months to 39 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced May 22, 2026, 2:44 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Arnold-Chiari Malformation, Posterior Fossa Tumors
Interventions
IV acetaminophen, normal saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced May 22, 2026, 2:44 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
Diagnostic Test · Drug · Other
Lead sponsor
Taproot Health
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Idaho Falls, Idaho • Laredo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Cerebellar Tumors, Brain Tumor
Interventions
Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 2:44 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Glioma
Interventions
LBH589
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
2 Years to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced May 22, 2026, 2:44 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Progressive or Refractory High-Grade Glioma
Interventions
Crenolanib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Months to 21 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced May 22, 2026, 2:44 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Untreated Childhood Medulloblastoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
cisplatin, cyclophosphamide, vincristine sulfate, etoposide, therapeutic conventional surgery, 3-dimensional conformal radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 3 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced May 22, 2026, 2:44 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Brainstem Glioma
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced May 22, 2026, 2:44 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Glioma, Brain Neoplasms
Interventions
Vioxx
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced May 22, 2026, 2:44 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer, Pediatric Brain Tumor, Diffuse Glioma
Interventions
Marizomib, Panobinostat
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced May 22, 2026, 2:44 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms, Astrocytoma, Astrocytoma, Cerebellar, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Cerebellar PNET, Childhood, Cerebellar Neoplasms, Cerebellar Neoplasms, Primary, Cerebellar Neoplasm, Malignant, Cerebellar Neoplasm Malignant Primary, Neoplasm Metastases, Neoplasm Malignant, Neoplasms, Neuroepithelial, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Central Nervous System Neoplasms, Primary, Central Nervous System Neoplasms, Malignant, Nervous System Neoplasms, Neoplasms by Site, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Medulloblastoma Recurrent, HSV, Virus, Pediatric Brain Tumor, Nervous System Cancer, Primitive Neuroectodermal Tumor (PNET) of Cerebellum
Interventions
G207
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
Interventions
CLR 131
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
Palo Alto, California • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM), Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Osteosarcoma, Hepatic Tumors, Hepatoblastoma, Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Rhabdomyosarcoma
Interventions
Cobolimab, Dostarlimab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
0 Years to 21 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Iowa City, Iowa • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced May 22, 2026, 2:44 AM EDT